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Introduction
The major biological effect ascribed to interleukin-16
(IL-16), a soluble ligand for CD4, is as a chemoattractant
for a wide range of CD4+ cells such as lymphocytes,1
eosinophils,2 monocytes/macrophages3 and dendritic
cells.4 Interleukin-16 can activate CD4+ T cells if it is
provided with IL-2.5 In contrast, the pretreatment of
CD4+ T cells with IL-16 reduces proliferation induced via
T-cell receptor/CD3 cross-linking6 and suppresses IL-2
production7 while increasing the expression of CD25
(IL-2Ra) by CD4+ T cells and human leucocyte antigen-
DR on CD4+ T cells and monocytes.3 Interleukin-16 also
inhibits the replication of human immunodeficiency virus
type 18 and stimulates proinflammatory cytokine produc-
tion by monocytes.9
Interleukin-16 is produced by an ever-growing list of
cell types including CD8+ and CD4+ T cells,10,11 epithelial
cells,12 dendritic cells,4 monocytes,13 synovial fibroblasts,14
mast cells15 and B cells.16 More than 90% of circulating
CD4+ and CD8+ T cells constitutively produce IL-16
although most of this is the 80 000 molecular weight, bio-
logically inactive pro-IL-16.11 Upon cellular activation,
pro-IL-16 is cleaved to a monomer of 14 000–17 000
molecular weight that then forms biologically active tetra-
mers.17 Caspase 3, itself needing cleaving from the
inactive pro-Caspase 3 form, mediates the cleavage of
pro-IL-16.18 Despite the well-established role for Caspase
3 in apoptosis and the release of IL-16, a link between
secretion of active IL-16 and apoptosis has only been
demonstrated for monocytes.13
Given its chemotactic effect on CD4+ T and non-T cells
it is not surprising that a role for IL-16 has been postu-
lated for a number of diseases including acquired
immune deficiency disease,19 asthma,20 rheumatoid
arthritis14 and systemic lupus erythematosus.21 The role
of IL-16 in normal physiology is also a focus of attention
with IL-16 identified as having a potential role in the
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Summary
CD4-positive cells are detectable in the human fetal gastrointestinal tract
from 11 weeks of gestation. Interleukin-16 (IL-16) is a chemoattractant
for CD4+ cells and, via fetal swallowing of amniotic fluid, could mediate
the influx of CD4+ cells into the fetal gut. We have shown that IL-16 was
detectable in human amniotic fluid at 16–18 weeks of gestation (mid-
pregnancy) but was not detectable at term (late pregnancy; > 37 weeks of
gestation). Similarly, mid-pregnancy, but not late pregnancy, amniotic
fluid contained chemotactic activity for CD4+ T cells, this activity was
reduced by 58% in the presence of a neutralizing anti-IL-16 antibody.
The levels of IL-16 in fetal plasma at 16–24 weeks of gestation were very
high, and decreased significantly by 25–36 weeks but at > 37 weeks
remained significantly higher than adult levels. IL-16 transcripts were
detectable in whole tissue extracts of fetal gut, skin and placenta but not
in amniocytes, and IL-16 immunoreactivity was detectable in cells within
the lamina propria of the fetal gut and within the skin, where it was asso-
ciated with the basement membrane. Neither IL-16 levels nor chemotactic
activity for CD4+ T cells in mid-pregnancy amniotic fluid was related to
atopic outcomes at 1 year of age. IL-16 might have an important role in
the early development of the human immune system and/or in regulating
fetal and maternal immunological responsiveness during pregnancy.
Keywords: amniotic fluid; atopy; chemotaxis; interleukin-16; pregnancy
 2009 Blackwell Publishing Ltd, Immunology, 126, 543–551 543
IMMUNOLOGY OR IG INAL ART ICLE
trafficking of dendritic cells and the formation of den-
dritic cell and T-cell clusters,4 as well as clusters including
B cells.16 Moreover, IL-16 can inhibit immunoglobulin E
(IgE) production22 and modify cytokine outputs by aller-
gen-stimulated peripheral blood mononuclear cells
including down-regulation of IL-5 and IL-13 but not IL-4
and up-regulation of interferon-c.23,24 CD4-independent
effects for IL-16 have been identified using CD4 knockout
mice25 and this is likely to lead to the elaboration of fur-
ther roles for IL-16 in the immune response and immune
homeostasis.
As the human fetal gut contains a large population of
CD4+ cells from approximately 11 weeks of gestation26
we postulated that the migration of these cells into the
gut could occur under the influence of IL-16 swallowed
in amniotic fluid. Furthermore, amniotic fluid IL-16
could similarly mediate the migration of CD4+ cells into
the fetal skin, which is also exposed to this fluid. The
presence of IL-16 in amniotic fluid has already been
observed with a decline in levels over gestation and ele-
vated levels in preterm and term amniotic fluid when
there was evidence of microbial invasion of the amniotic
cavity noted.27 Circulating IL-16 is elevated in women
with pre-eclampsia,28,29 and IL-16-positive microglia have
been demonstrated in the human fetal brain from 11 to
20 weeks of gestation.30 Tissue-specific, stage-dependent
distribution of IL-16 at the materno–fetal interface has
also been demonstrated during murine pregnancy.31 We
have therefore measured IL-16 (both protein and chemo-
tactic activity) in amniotic fluid and evaluated the pres-
ence of CD4+ cells within both fetal gut and skin.
Additional investigation has considered the possible
sources of amniotic fluid IL-16 as well as the potential
contribution of this cytokine to the subsequent develop-
ment of an atopic phenotype.
Materials and methods
Tissue, blood and amniotic fluid samples
Samples of human fetal gut (n = 12) and skin (n = 11)
were obtained via the Medical Research Council tissue
bank from suction or dilatation/evacuation terminations.
Gestational age (last menstrual period) was determined
anatomically by foot length. Tissue was snap frozen in
liquid nitrogen and stored until use. Fetal blood was col-
lected by umbilical vein or cardiac puncture from fetuses
delivered for medical reasons using prostin (n = 8). Blood
was also collected by umbilical vein puncture from neo-
nates delivered at term (n = 17) and prematurely
(n = 21), and by venepuncture from healthy adult con-
trols (n = 16). Amniotic fluid and peripheral blood were
collected using standard procedures from women under-
going diagnostic amniocentesis at 16–18 weeks of gesta-
tion (n = 20) and also from women undergoing elective
Caesarean section at term (n = 16). Only amniotic fluid
samples from pregnancies with no indication of fetal
abnormality were included in this study. Cell-free amni-
otic fluid was prepared by centrifugation at 900 g and
then stored at )80 until analysis. All bloods were col-
lected into lithium heparin and plasma was obtained by
centrifugation at 900 g for 10 min at room temperature.
Plasma was filtered, divided into aliquots and stored at
)80 until analysis. The study was approved by the
Southampton and S.W. Hants Joint Research Ethics Com-
mittee and fulfilled the requirements of the Polkinghorne
Committee report on the research use of fetuses and fetal
tissues.
Immunohistochemistry
Tissue sections (8 lm) were cut at the cryostat onto poly-
L-lysine-coated slides, air-dried and then fixed in acetone
for 10 min at room temperature. After blocking in 03%
H2O2 in 01% sodium azide for 10 min, three 2-min
washes in Tris-buffered saline and a further blocking incu-
bation in 10% rabbit serum in Tris-buffered saline, 100 ll
of primary antibody, at a preoptimized dilution, was
applied to the slide for 30 min. The slides were washed as
before and biotinylated rabbit anti-mouse immunoglobu-
lins (Dako Ltd, Cambridge, UK) were applied for 30 min
incubation at room temperature. After further washes,
streptavidin biotin–peroxidase complexes (Dako Ltd) were
applied for 30 min at room temperature before washing
and the visualization of immunoreactivity with chromogen,
either aminoethyl carbazole or diaminobenzidine (Bioge-
nex, San Ramon, CA). Sections were counterstained with
Mayer’s haematoxylin, dehydrated and mounted in DPX
(BDH, Dorset, UK) for viewing. Antibodies (at previously
optimized concentrations) used were monoclonal anti-
human CD3 (mIgG1, clone UCHT1; Dako Ltd), anti-
human CD4 (mIgG1, Leu-3a; BD Biosciences, Oxford,
UK), and anti-IL-16 (mIgG1, clone 15B2; Alexis, Notting-
ham, UK). An isotype control (mIgG1, clone MOPC-21;
BD Biosciences) was always included.
IL-16 enzyme-linked immunosorbent assay
The IL-16 in amniotic fluid and plasma samples was mea-
sured using a commercially available IL-16-specific
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s instructions (Biosource, Invitrogen,
Oxford, UK). All samples were assayed at a dilution of
1 in 2 in the dilution buffer provided and the sensitivity
of the assay was 23 pg/ml.
Chemotaxis assay
CD4+ T cells were isolated from venous blood collected
from healthy adult donors into lithium heparin. After
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preparation of peripheral blood mononuclear cells on
Histopaque (Sigma, Dorset, UK), CD4+ T cells were iso-
lated using the CD4+ T-cell isolation kit and LS+ col-
umns for midiMACs (Miltenyi Biotec, Bisley, UK). The
purity of the enriched population was assessed using flow
cytometry (CELLQUEST on FACscan, BD Biosciences) and
was routinely found to be > 95% CD4+ CD3+ T cells.
Cells were washed and resuspended in RPMI-1640 with
Glutamax, 100 U/ml penicillin, 100 lg/ml streptomycin
and 01% human serum albumin (chemotaxis assay
buffer) at 2 · 106 cells/ml.
T-cell chemotaxis was assayed using 5 lm pore poly-
vinylpyrrolidone-free polycarbonate filters (Costar; Corn-
ing Incorporated, Corning, NY) in micro-Boyden
chambers. A serial dilution of recombinant human IL-16
(R&D Systems, Abingdon, UK) of 01 pg/ml to 1 lg/ml
was prepared in chemotaxis assay buffer and amniotic fluid
was diluted (neat, 1/2, 1/10, 1/100) in chemotaxis assay
buffer and added to the lower wells of the assay chamber
in triplicate. The filter was fixed in place, enriched CD4+ T
cells were added (100 000/well) and the chamber was
incubated for 2 hr at 37 in 5% CO2 in air. The filter was
then removed, washed in phosphate-buffered saline and
scraped to remove the cells on the upper surface of the
filter, then the migrated cells adherent to the lower side
were fixed in methanol and stained (Hema–Gurr; BDH).
The numbers of cells in each of five high-power (· 400)
fields were counted and the value obtained from control
wells (buffer only) was subtracted. Neutralizing experi-
ments were conducted by pretreating the sample (amniotic
fluid final concentration 1 in 10) with goat polyclonal anti-
IL-16 antibody (10 lg/ml final concentration; R&D
Systems) for 45 min at room temperature. The ability to
neutralize recombinant human IL-16 was assessed as a
positive control. An isotype control (goat IgG; R&D
Systems) at the same concentration was included.
Reverse transcription–polymerase chain reaction
RNA was extracted from blood and tissue samples using
RNase-free DNase treatment with the RNeasy total RNA
isolation system as directed by the manufacturer (Qiagen
Ltd, Crawley, UK). First strand complementary DNA
(cDNA) synthesis was performed with 05 lg of total
RNA in a 20 ll reaction using the Omniscript reverse
transcriptase kit (Qiagen Ltd.) primed with oligo-
T17(AGC) (Sigma Genosys, Cambridge, UK), all as rec-
ommended by the manufacturer. RNA was preheated to
60 for 5 min to remove secondary structures, then
placed on ice. Reverse transcription was carried out for
60 min at 37.
Polymerase chain reactions (PCR) were performed in a
total reaction volume of 25 ll using 1 ll of cDNA in buf-
fer containing 10 mM Tris–HCl, pH 83, 50 mM KCl,
0001% gelatin, with 2 mM MgCl2, 200 mM dNTP, 02 lM
of each primer and 0625 U Taq DNA polymerase (Sigma
Genosys). For IL-16 PCR, amplification was performed
with an initial denaturation of 94 for 2 min followed by
30 cycles of 94 for 20 seconds, 61 for 30 seconds, 72
with a final extension of 72 for 10 min. Primers for
IL-16 were: forward, 50-GGCATCCATGTCACCATCTTA-30,
and reverse, 50-AGACTGTGGCCTCTGCTGTAGA-30. For
b-actin, amplification was performed as above but with a
final concentration of MgCl2 of 15 mM for 30 cycles at an
annealing temperature of 54 with the primers for b-actin,
forward, 50-TGATATCGCCGCGCTCGT-30, and reverse,
50-CTCGGCCGTGGTGGTGAA-30. Products were resolved
on a 2% agarose gel, stained with ethidium bromide and
imaged using a fluorimager 595 (Molecular Dynamics, GE
Healthcare Ltd, Amersham, Buckinghamshire, UK).
Clinical evaluation
Clinical assessment of the infants was conducted at 1 year
of age (by N.D.D. and J.O.W.). The children were
weighed, measured and a physical examination was per-
formed. Skin prick testing to Dermataphagoides pteronyssi-
nus, Felix domesticus, grass pollen mix, tree pollen mix,
cow’s milk and hen’s egg (ALK-Abello, Hørsholm, Den-
mark) was conducted on each child. A negative control
(allergen diluent) and a positive control (10 mg/ml hista-
mine; ALK) were always included. A child was considered
atopic if a wheal of  3 mm was observed in response to
any of the allergens used in the presence of an appropri-
ate response to the positive and negative control. All the
skin-prick-test-positive children included in the analysis
also had eczema (n = 10) and the skin-prick-test-negative
children were eczema-free (n = 10).
Statistics
Mann–Whitney U-test and Kruskall–Wallis were used for
non-parametric statistical evaluation (SPSS version 10;
SPSS Inc., Chicago, IL) for Windows software.
Results
Amniotic fluid IL-16
Amniotic fluid collected from women undergoing diag-
nostic amniocentesis at 16–18 weeks (n = 20) had signifi-
cantly higher levels of immunoreactive IL-16 than
amniotic fluid collected during elective Caesarean section
at term (n = 16; P < 0001; Fig. 1a).
Bioactivity of IL-16 in amniotic fluid was assessed using
chemotaxis for adult CD4+ T cells. Chemotactic activity
was significantly greater (P = 00006) in amniotic fluid at
16–18 weeks of gestation compared to that collected at
term (13476 ± 1767 cells per field of view for 16–18
weeks amniotic fluid diluted 1 in 2 versus 2179 ± 1353
 2009 Blackwell Publishing Ltd, Immunology, 126, 543–551 545
IL-16 in human amniotic fluid
cells per field of view for term amniotic fluid diluted 1 in
2; mean ± SEM; n = 6 per group). Chemotactic activity
for CD4+ cells was observed in early gestation amniotic
fluid to a dilution of 1 in 100 (Fig. 1b).
Neutralizing experiments were conducted with mid-
pregnancy amniotic fluid using a goat polyclonal anti-
IL-16 antibody. Lower levels of chemotactic activity for
CD4+ T cells were observed in the presence of neutraliz-
ing anti-IL-16 antibody with each of the donors tested
(n = 5; Fig. 1c). Overall, the chemotactic activity of amni-
otic fluid for CD4+ T cells was significantly lower
(P = 00006) in the presence of neutralizing anti-IL-16
(4209 ± 695%; mean ± SEM; n = 5) than in the absence
of neutralizing antibody/presence of isotype control
(9967 ± 788%; mean ± SEM; n = 5). The isotype con-
trol antibody had a negligible effect on chemotaxis.
Source(s) of amniotic fluid IL-16
As the skin is semi-permeable until approximately
25 weeks of pregnancy when keratinization is complete32
the fetal circulation may be a source of IL-16, which dif-
fuses into the amniotic fluid. Circulating IL-16 levels in
early gestation (16–24 weeks; n = 8) were the highest of all
the plasma samples studied (Fig. 2; median 77098 pg/ml,
range 13379–204688 pg/ml; P < 0001 in comparison to
all other ages studied). Although levels decreased with
increasing gestational age, circulating levels at 25–36 weeks
(n = 21; median 10066 pg/ml, range 3019–23049 pg/ml;
P < 0005) and at term (> 37 weeks gestation; n = 17;
median 8219 pg/ml, range 2699–34776 pg/ml; P <
0005) remained significantly higher than in the adult (n =
16; median 3491 pg/ml, range 1412–50518 pg/ml).
The possible contribution of the fetal skin and gut to
amniotic fluid IL-16 levels was then assessed. Interleukin-
16-positive cells were present in the lamina propria of the
fetal gut (Fig. 3a) and in the dermis of fetal skin IL-16
immunoreactivity was localized to the basement mem-
brane of the epidermis (Fig. 3c). To confirm these tissues
as the source of IL-16 the expression of messenger RNA
within whole tissue homogenates was examined. Tran-
scripts for IL-16 were detected in fetal gut and skin at
13–16 weeks of gestation as well as in the placenta at
16–21 weeks of gestation, but not in amniocytes prepared
from amniotic fluid (Fig. 4). Adult CD4+ T cells were
used as a positive control.
CD4 immunoreactivity in human fetal tissues
There was an abundance of CD4+ cells in the human fetal
gut from as early as 11 weeks of gestation until at least
15 weeks of gestation (the latest time-point examined
here; n = 12; Fig. 5a) and the CD4+ cells were localized at
the lumenal edge of the lamina propria. Human fetal skin
at the same gestational age range had fewer CD4+ cells
than the gut and immunoreactivity was not localized to
the edge in contact with amniotic fluid (Fig. 5d). There
were far fewer CD3+ than CD4+ cells in the fetal gut and
CD3+ cells were essentially absent from the fetal skin
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Figure 1. Interleukin-16 (IL-16) levels and chemotactic properties of
amniotic fluid at different times of gestation. Amniotic fluid collected
at 16–18 weeks of gestation and at term were analysed for (a) IL-16
levels by enzyme-linked immunosorbent assay, and (b) chemotactic
properties for CD4+ T cells by chemotaxis assay as described inMateri-
als and methods. For chemotaxis assays samples were assayed neat or
diluted 1 in 2, 10 or 100 using amniotic fluid from 16 to 18 weeks of
pregnancy (PAF) and > 37 weeks of pregnancy (TAF). (c) The contri-
bution of IL-16 to chemotactic properties of early pregnancy amniotic
fluid was determined using a neutralizing anti-IL-16 polyclonal anti-
body (n = 5). The amount of preterm amniotic fluid-mediated (PAF)
chemotaxis in the presence of neutralizing antibody is shown as a per-
centage of that seen with amniotic fluid alone (black bar) as is the
amount seen in the presence of the isotype control (open bars). A posi-
tive control (IL-16; 1 pg/ml) is also included.
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(Fig. 5b,e). Immunoreactivity was not seen in the isotype
control treated samples of gut and skin (Fig. 5c,f).
Amniotic fluid IL-16, chemotactic activity and atopic
disease
The variability in both IL-16 levels and the contribution
to the chemotactic effect of amniotic fluid on CD4+ T
cells prompted us to investigate if the chemotactic pro-
perties of amniotic fluid and IL-16 levels within the fluid
were associated with atopic disease development post-
natally. There was no difference in either IL-16 levels
(Fig. 6a) or chemotactic activity for CD4+ T cells
(Fig. 6b) in amniotic fluid collected at 16–18 weeks of
gestation in infants who had a positive skin prick test at
1 year of age (n = 10) compared to those who remained
skin-prick-test-negative (n = 10). There was no correla-
tion between IL-16 protein levels and the chemotactic
properties of the amniotic fluid sample (Spearman’s
r = 0291; not significant) either when analysing the sam-
ple series as a complete set, or separately for atopic versus
non-atopic outcome.
Discussion
The abundance of CD4+ cells within fetal tissues
prompted us to consider the possible role of IL-16 in
mediating this infiltration into early gestation tissues.
IL-16 was present in amniotic fluid obtained at a gesta-
tion similar to the fetal tissue samples (16–18 weeks of
gestation) from women undergoing diagnostic amniocen-
tesis. However, IL-16 was not detectable in term amniotic
fluid samples collected from women undergoing elective
Caesarean section. Another study has also reported a
decline in human amniotic fluid IL-16 levels during gesta-
tion.27 At approximately 25 weeks of gestation amniotic
fluid undergoes a dramatic change in composition, as
fetal urine becomes the major contributor.32 Whether the
decline in amniotic fluid IL-16 also occurs at this time
needs to be assessed, although the limitations of working
with samples from humans might make this difficult to
ascertain.
This is the first study to demonstrate that amniotic
fluid IL-16 is biologically active. Chemotaxis assays using
adult CD4+ T cells were used to evaluate if amniotic fluid
IL-16 was biologically active. The bioassay results paral-
leled the immunoassay results, with the ability to induce
the chemotaxis of adult CD4+ T cells being virtually
restricted to mid-pregnancy amniotic fluid. Neutralizing
experiments confirmed that IL-16 contributed to this
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Figure 2. Interleukin-16 (IL-16) levels in fetal plasma throughout
pregnancy. Circulating IL-16 levels at different gestational ages were
measured by enzyme-linked immunosorbent assay and compared to
adult levels. **P < 0001 and *P < 0005 denote statistically signifi-
cant difference to adult levels.
(a) (c)
(b) (d)
Figure 3. Interleukin-16 (IL-16) immunoreac-
tivity in fetal gut and skin. A monoclonal
anti-IL-16 antibody was used to immunohisto-
chemically stain sections of fetal (a) gut or (c)
skin. An isotype control (b and d) was always
included and a representative example is
shown. Positively stained cells and localization
of IL-16 immunoreactivity to the basement
membrane in the fetal skin are highlighted
with arrows. Inset in (c) is higher magnifica-
tion of IL-16 immunoreactivity in the skin.
Scale bar, 05 mm.
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activity, accounting for 58% of the response measured.
Other chemokines have been identified within human
amniotic fluid, namely IL-8 and RANTES (regulated on
activation normal T cell-expressed and secreted).33,34
Although IL-8 is best known for its chemotactic effect on
neutrophils, both it and RANTES can mediate the chemo-
taxis of T cells and may be contributing to the response
we observed.35 The contribution of other chemokines to
this biological property of amniotic fluid remains to be
evaluated.
Where does amniotic fluid IL-16 come from? We ini-
tially ruled out amniocytes (fetally derived cells in the
amniotic fluid) showing that this population did not con-
tain transcripts for IL-16. Fetal plasma could contribute
to amniotic fluid IL-16 as the skin in early to mid-gesta-
tion readily allows diffusion. As fetal circulating IL-16
levels were very high at 16–24 weeks of gestation, corre-
sponding with abundant levels of IL-16 in amniotic fluid
at this time, there could be interchange of IL-16 between
the circulation and the amniotic fluid.
Mirroring amniotic fluid levels, fetal circulating levels
declined over gestation, although plasma levels at term
(as well as earlier in gestation) remained significantly
higher than in the adult circulation. In addition to the
possible passive diffusion of IL-16 across the fetal gut and
skin, cells within these tissues, and the placenta, could
contribute to amniotic fluid IL-16. Immunoreactivity of
IL-16 was observed in the gut and skin, implicating both
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Figure 4. Expression of interleukin-16 (IL-16) transcripts within fetal
tissues. RNA extracted from fetal gut, skin and placental tissue as
well as from amniocytes prepared from amniotic fluid was examined
for the expression of transcripts of IL-16 at various ages of gestation.
Analysis of the expression of transcripts of a house-keeping gene
(b-actin) was included for each sample.
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Figure 5. CD4 and CD3 immunoreactivity
within human fetal gut and skin. Tissue sec-
tions from fetal gut and skin at were stained
with monoclonal antibodies to CD4 [gut (a)
and skin (d)], CD3 [gut (b) and skin (e)] or
an isotype control [gut (c) and skin (f)]. A
representative sample of 15 weeks gestation is
shown. Scale bar, 05 mm.
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of these sites as possible sources of amniotic fluid IL-16.
The IL-16-positive cells were dispersed throughout both
tissues but in the skin, although positive cells were
observed throughout the dermis, IL-16 immunoreactivity
was localized to the basement membrane of the forming
epidermis. To confirm that cells within the gut and skin
were producing IL-16 and not just storing amniotic fluid-
derived or fetal plasma-derived IL-16 we showed that
transcripts for IL-16 were detectable within these tissues
at the appropriate gestational ages. Caution should be
employed in interpreting results from the placenta
because it is difficult to wash all the blood out of this
tissue and the IL-16 transcripts could reflect contamina-
tion with maternal or fetal blood cells. Only in situ
hybridization and immunohistochemistry would allow
identification of IL-16 production by cell populations
within the placenta.
The observation of IL-16 localized to the epidermal
basement membrane could have dramatic consequences
for the biological activity of IL-16 at this site. The seques-
tering of a number of chemokines and cytokines by
basement membranes has been observed, including
macrophage inflammatory protein-1b and IL-4.36,37 Func-
tionally, this sequestration could either limit the biologi-
cal effect of the cytokine or generate very high local
concentrations of biologically active mediator, depending
on the nature of the proteoglycan core protein or glycos-
aminoglycan to which the cytokine is bound within the
extracellular matrix. It is interesting that the association
of IL-16 with the basement membrane did not occur in
the fetal gut, suggesting that the extracellular matrix com-
ponent to which IL-16 binds is differentially expressed in
the gut and skin. Moreover, the one study of IL-16
messenger RNA expression in human adult skin found
transcripts for this cytokine within the basal layer of the
epidermis but unfortunately did not examine protein
expression.38 However, in mycosis fungoides IL-16
immunoreactivity was evident in the T cells infiltrating
the skin but not in other cell types from the epidermis
and dermis.39 It will be necessary to conduct a direct
comparison of fetal and adult skin to determine possible
developmental differences in IL-16 expression within the
skin.
From around 11 weeks of gestation the human fetal gut
contains a large population of CD4+ cells that are localized
at the lumenal edge of the lamina propria (Fig. 5a). We did
not further identify the CD4+ cells in the fetal gut because
the focus of this investigation was IL-16 bioactivity and
IL-16 interacts with the CD4 surface antigen irrespective of
the cell type; however, work by others has shown that the
majority of these CD4+ cells do not express CD3 and are
likely to be macrophages.26 The distribution of CD4+ cells
at the lumenal edge suggests that these cells could be
responding to chemoattractants, such as IL-16, within the
amniotic fluid that the fetus swallows. If mediators within
the amniotic fluid could influence CD4+ cell trafficking to
the gut this effect might well extend to the skin, which is
also exposed to amniotic fluid. Indeed, CD4+ cells were
detectable within the fetal skin at equivalent gestational
ages but the infiltrate of CD4+ cells was not as extensive in
the fetal skin nor did it show localization to the tissue edge
in contact with the amniotic fluid.
Extracellular matrix binding by IL-16 and attenuation
of IL-16 bioactivity in the skin could explain the differ-
ences in abundance of CD4-positive cells at each site
despite the skin being exposed to more IL-16. This differ-
ence could also be explained in a number of other ways.
The skin and the gut might simply have different rates of
development. The gut is considered structurally mature at
19 weeks of gestation which is earlier than the skin, where
keratinization is not complete until approximately
25 weeks of gestation.32,40 Alternatively, biological assays
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Figure 6. The association between interleukin-16 (IL-16) levels and
chemotactic properties of early pregnancy amniotic fluid and atopy
outcome at 1 year of age. Clinical assessment of children born to
mothers who had undergone amniocentesis was conducted and the
skin prick test (SPT) result obtained at 1 year of age was compared
to 16 week amniotic fluid (a) IL-16 levels and (b) chemotactic prop-
erties for CD4+ T cells. There was no difference between the groups
(n = 10/group).
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of chemotactic factors indicate that these molecules char-
acteristically have bell-shaped curves such that high doses
no longer exert any chemotactic effect on the cell popula-
tion being studied. As the skin has greater exposure to
amniotic fluid than the gut, local concentrations in the
skin might well be higher than in the gut and the chemo-
tactic effect of IL-16 in the skin might, therefore, be lim-
ited. Finally, amniotic fluid IL-16 might not have a role
in chemotaxis at this site. Interleukin-16 has many
immunoregulatory properties including down-regulation
of CD3-stimulated proliferation by T cells and IL-16 in
amniotic fluid and the fetal circulation might be part of
the immunoregulatory milieu of pregnancy that regulates
maternal and fetal immune responsiveness. Naturally
occurring CD4+ CD25+ regulatory T cells have been
implicated in the maintenance of maternal immunological
tolerance to the fetus41 and IL-16 has been shown to
favour the migration of this cell type and to induce
expression of Forkhead box P3 (FoxP3).42
All the babies born onto the study for which amniotic
fluid was collected during amniocentesis are undergoing
clinical follow-up for the development of atopic disease. As
the first manifestations of atopic disease commonly occur
in the gastrointestinal tract and/or skin during the first year
after birth, the early development of both of these tissues
might be critical to the later expression of disease. To date,
a small number of 1-year-olds in this birth cohort have
been identified as skin-prick-test-positive (with eczema) to
common environmental allergens, i.e. atopic. Neither the
levels of IL-16 nor the CD4+ T-cell chemotactic property
of amniotic fluid from these infants differed from that of
amniotic fluid from infants who remained skin-prick-test-
negative (and eczema-free) at 1 year of age. Therefore, the
IL-16 levels at 16–18 weeks of gestation do not differ with
regard to the development of atopy by 1 year of age
although the number included in this analysis is very small.
Moreover, there was not a significant correlation between
IL-16 levels and chemotactic properties of the amniotic
fluid, suggesting that other chemoattractants variably con-
tribute to the response observed and could differ between
future atopic and non-atopic children. As chemokines and
other molecules with chemoattracting properties might
exert their influence on other non-CD4+ T-cell populations
these might have a disease association.
This study shows that mid-gestation human amniotic
fluid is an abundant source of immunoreactive IL-16, and
neutralization studies reveal that this cytokine accounts for
approximately 60% of the CD4+ T-cell chemotactic prop-
erties of human amniotic fluid at 16–18 weeks of gestation.
Whether it is a biological mediator of chemotaxis by CD4+
T-cell and non-T-cell populations in the fetal gut in vivo
remains to be determined, as does the identity of other
chemoattractants within amniotic fluid that could contrib-
ute to this response. Numerous biological effects have now
been described for IL-16, and as IL-16 can stimulate the
production of proinflammatory cytokines by monocytes
and support the migration of Langerhans cells harvested
from CD4 knockout mice it is likely to have additional
CD4-independent effects.25,43 The abundance of IL-16 in
early pregnancy amniotic fluid as well as in the fetal
circulation throughout gestation might modify fetal and
neonatal immunological functions. Understanding these
mechanisms will aid in the identification of perturbations
that might contribute to the development of various dis-
eases, especially those that are first manifest in childhood.
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